体外心肺复苏在心脏骤停患者中的成本-效用分析
本研究回顾性分析了2012年至2018年在本机构因心脏骤停接受体外心肺复苏(ECPR)的32例患者(院内心脏骤停15/32,47%),中位年龄55.0岁(IQR 46.3-63.3岁),男性59%,非裔美国人66%。ECPR中位支持时长2.1天(IQR 0.9-3.8天),出院存活率16%;存活者出院时健康效用指数Mark II中位评分0.44(IQR 0.32-0.52)。接受ECMO患者的中位操作成本为每例125683美元(IQR 49751-206341美元),计算得到ECPR的成本-效用为每获得1个QALY 56156美元。作者结论认为该成本-效用处于美国认为具有成本效果的阈值内(<150000美元/QALY),与终末期心力衰竭心脏移植的成本效果相当,并指出需要更大规模的研究评估ECPR的成本-效用及患者特征等其他因素是否影响成本-效用获益。
要点
- 本中心2012-2018年32例心脏骤停ECPR患者,出院存活率16%,中位ECPR支持时长2.1天(IQR 0.9-3.8天)。
- 存活者出院时健康效用指数Mark II中位评分0.44(IQR 0.32-0.52)。
- ECMO患者中位操作成本每例125683美元(IQR 49751-206341美元),ECPR成本-效用为56156美元/QALY。
- 作者认为该成本-效用低于美国成本效果阈值(<150000美元/QALY),与终末期心衰心脏移植的成本效果相当。
- 作者指出需要更大规模研究评估ECPR成本-效用及患者特征等其他因素是否影响成本-效用获益。
适用人群与场景
- 2012年至2018年在本机构因心脏骤停接受ECPR的患者,共32例,其中院内心脏骤停15/32(47%),中位年龄55.0岁(IQR 46.3-63.3岁),男性59%,非裔美国人66%。
研究设计与关键结果
- 研究类型:回顾性研究,单中心,纳入2012年至2018年接受ECPR的心脏骤停患者32例(院内心脏骤停15/32,47%),中位年龄55.0岁(IQR 46.3-63.3岁),男性59%,非裔美国人66%。
- ECPR中位支持时长2.1天(IQR 0.9-3.8天);出院存活率16%。
- 存活者出院时健康效用指数Mark II中位评分0.44(IQR 0.32-0.52)。
- 接受ECMO患者的中位操作成本为每例125683美元(IQR 49751-206341美元)。
- ECPR的成本-效用为每获得1个QALY 56156美元。
证据类型、等级与局限
- 证据类型:回顾性研究;局限:原文未报告局限性;作者结论指出需要更大规模的研究评估ECPR的成本-效用,并识别患者特征等其他因素是否影响成本-效用获益。
对床旁实践的改变
- 作者认为,计算得到的成本-效用处于美国认为具有成本效果的阈值内(<150000美元/QALY),并与终末期心力衰竭心脏移植的成本效果相当。
- 作者指出,需要更大规模的研究评估ECPR的成本-效用,并识别患者特征等其他因素是否影响成本-效用获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal cardiopulmonary resuscitation (ECPR) is a resource-intensive tool that provides haemodynamic and respiratory support in patients who have suffered cardiac arrest. In this study, we investigated the cost-utility of ECPR (cost/QALY) in cardiac arrest patients treated at our institution.
METHODS: We performed a retrospective review of patients who received ECPR following cardiac arrest between 2012 and 2018. All medical care-associated charges with ECPR and subsequent hospital admission were recorded. The quality-of-life of survivors was assessed with the Health Utilities Index Mark II. The cost-utility of ECPR was calculated with cost and quality-of-life data.
RESULTS: ECPR was used in 32 patients (15/32 in-hospital, 47%) with a median age of 55.0 years (IQR 46.3-63.3 years), 59% male and 66% African American. The median duration of ECPR support was 2.1 days (IQR 0.9-3.8 days). Survival to hospital discharge was 16%. The median score of the Health Utilities Index Mark II at discharge for the survivors was 0.44 (IQR 0.32-0.52). The median operating cost for patients undergoing ECMO was $125,683 per patient (IQR $49,751-$206,341 per patient). The calculated cost-utility for ECPR was $56,156/QALY gained.
CONCLUSIONS: The calculated cost-utility is within the threshold considered cost-effective in the United States (<$150,000/QALY gained). These results are comparable to the cost-effectiveness of heart transplantation for end-stage heart failure. Larger studies are needed to assess the cost-utility of ECPR and to identify whether other factors, such as patient characteristics, affect the cost-utility benefit.
参考来源
- Bharmal MI, Venturini JM, Chua RFM, et al. Cost-utility of extracorporeal cardiopulmonary resuscitation in patients with cardiac arrest. Resuscitation. 2019. PMID: 30716427. doi:10.1016/j.resuscitation.2019.01.027
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。